|
ISIN No
|
INE646B01010
|
BSE Code / NSE Code
|
531146 / MEDICAMEQ
|
Book Value (Rs.)
|
204.50
|
Face Value
|
10.00
|
|
Bookclosure
|
19/09/2026
|
52Week High
|
448
|
EPS
|
7.11
|
P/E
|
32.50
|
|
Market Cap.
|
313.34 Cr.
|
52Week Low
|
212
|
P/BV / Div Yield (%)
|
1.13 / 0.00
|
Market Lot
|
1.00
|
|
Security Type
|
Other
|
|
The company history sections lists out major chronological events that happened to the company.
| MBL was incorporated as a public limited company under the
Companies Act, 1956, on December 22, 1993. The certificate
of commencement of business was obtained on January 31,
1994. The company has jointly been promoted by Mr.V.Kumar,
Mr.Bal Kishan Gupta, Mr.Lakhvinder Singh Arora and
Mr.Ranjit Singh.
MBL is engaged in marketing of various drugs in the domestic
and export markets. Company is procuring drugs from various
reputed manufactures viz. Hoechst, Cadila, Hindustan Ciba,
Purepharma, Oboi Labs etc. and exporting to countries like
Germany, Russia, Holland, CIS (Confederation of Independent
States) etc. part from domestic ethical and institutional sales.
MBL has obtained permission for production of tablets, capsules
and liquid orals under loan licence basis from Delhi Drug Control
Authority and Madhya Pardesh Drug Control Authority on Welbeck
Pharmaceutical Private Limited, New Delhi and Pure Pharma Private
Limited, Indore respectively.
2010
-The Company has recommended a final dividend of Rs. 0.75 per equity share (being 7.5% on the face value of Rs. 10 per share)
-The Company appointed Mr. B.K.Gupta as Managing Director.
2011
-The Company gets ANVISA.Brazil approval for Non Beta Lactum solid Tablets and Coated tablets manufactured at its Plant situated at SP 1192,A & B, Phase 4, Bhiwadi - 301019, Rajasthan.
2013
-Ms. Harshita Sharma has been appointed as Additional Director of the company.
2016
-Shivalik Rasayan Ltd take controlling stake of Medicamen Biotech Ltd.
2019
-FABD(Philippines), CECMED(Cuba)-Bhiwadi FDF Plant.
2020
-Global API Facility started Dahej API Plant.
2021
-Operations started Haridwar formulation Unit II(FDF).
2023 -Medicamen Biotech Gains On Successful Anda Filing For Bortezomib Injections.
2024 -Medicamen Biotech's Bhiwadi Manufacturing Facility Secures EU GMP Approval from Greece. -Medicamen Biotech's Sterile injectable Facility Received USFDA Approval.
|